13.45
2.75%
0.36
After Hours:
13.45
Cullinan Therapeutics Inc Stock (CGEM) Forecast
The Cullinan Therapeutics Inc (CGEM) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $21.48, representing a +59.69% increase from the current price of $13.45. The highest analyst price target is $23.61, and the lowest is $19.35.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month CGEM Price Target
Average 12.24
(-9.02% Downside)
Is Cullinan Therapeutics Inc (CGEM) A Buy Now?
Oscillators
Name | Value | Action |
---|---|---|
RSI(14) | 41.01 | Neutral |
STOCH(9,6) | 23.10 | Neutral |
STOCHRSI(14) | 43.34 | Neutral |
MACD(12,26) | -0.9348 | Sell |
ADX(14) | 21.04 | Neutral |
William %R | -74.19 | Neutral |
CCI(14) | -28.65 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
Period | Simple | Exponential |
---|---|---|
MA10 |
12.96
Buy
|
13.36
Buy
|
MA20 |
14.49
Sell
|
14.11
Sell
|
MA50 |
15.68
Sell
|
15.40
Sell
|
MA100 |
16.84
Sell
|
16.42
Sell
|
MA200 |
18.28
Sell
|
16.14
Sell
|
Buy: 2
Sell: 8
Neutral: 0
Summary: Sell
According to our latest analysis, CGEM could be considered a Strong Sell, with 17 technical analysis indicators signaling 2 Buy signals, 9 signaling Sell signals and 6 Neutral signals. This might not be a good time to consider opening new positions on CGEM, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 41.01 indicates that CGEM is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 23.1 indicates that CGEM is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 43.34 indicates that CGEM is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 21.04 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -28.65 indicates that CGEM is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term CGEM price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Cullinan Therapeutics Inc financial reports and earnings history, Cullinan Therapeutics Inc (CGEM) stock could reach $0.8514 by 2030, $5.3308 by 2040 and $32.04 by 2050. See the projected annual prices until 2050 of the Cullinan Therapeutics Inc stock below:
- Cullinan Therapeutics Inc (CGEM) is expected to reach an average price of $8.6087 in 2035, with a high prediction of $8.2087 and a low estimate of $8.3325. This indicates an $-35.99% rise from the last recorded price of $13.45.
- Cullinan Therapeutics Inc (CGEM) stock is projected to chart a bullish course in 2040, with an average price target of $4.6745, representing an $-65.25% surge from its current level. The forecast ranges from a conservative $5.6769 to a sky-high $5.3308.
- Our analysts predict Cullinan Therapeutics Inc (CGEM) to jump 85.69% by 2045, soaring from $25.40 to an average price of $24.98, potentially reaching $24.88. While $25.40 is the low estimate, the potential upside is significant.
- Cullinan Therapeutics Inc (CGEM) stock is expected to climb by 2050, reaching an average of $31.54, a $134.47% jump from its current level. However, a wide range of estimates exists, with high and low targets of $32.04 and $31.58, respectively, highlighting the market's uncertainty.
Cullinan Therapeutics Inc Stock (CGEM) Year by Year Forecast
Cullinan Therapeutics Inc Stock (CGEM) Price Forecast for 2025
Cullinan Therapeutics Inc Stock (CGEM) is expected to reach an average price of $12.24 in 2025, with a high prediction of $23.61 and a low estimate of $0.8656. This indicates an -9.02% fall from the last recorded price of $13.45.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2025 | $19.71 | $19.35 | $23.61 | +46.54% |
February, 2025 | $17.15 | $15.27 | $19.34 | +27.49% |
March, 2025 | $16.50 | $13.68 | $18.37 | +22.65% |
April, 2025 | $9.5914 | $9.3514 | $17.27 | -28.69% |
May, 2025 | $8.8397 | $7.8056 | $11.38 | -34.28% |
June, 2025 | $6.2781 | $5.3081 | $11.88 | -53.32% |
July, 2025 | $7.9735 | $5.5635 | $8.4993 | -40.72% |
August, 2025 | $6.8318 | $5.0218 | $8.4756 | -49.21% |
September, 2025 | $5.2802 | $3.8731 | $7.0289 | -60.74% |
October, 2025 | $4.1856 | $0.8656 | $5.3173 | -68.88% |
November, 2025 | $5.144 | $3.5598 | $5.9627 | -61.75% |
December, 2025 | $6.5594 | $4.0381 | $7.391 | -51.23% |
Cullinan Therapeutics Inc Stock (CGEM) Price Forecast for 2026
The predicted value for Cullinan Therapeutics Inc (CGEM) in 2026 is set at an average of $5.6532. Estimates vary from a peak of $9.5406 to a trough of $1.7657, indicating an -57.97% surge from the present price of $13.45.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2026 | $7.1677 | $6.3965 | $9.5406 | -46.71% |
February, 2026 | $6.4961 | $6.294 | $8.7119 | -51.70% |
March, 2026 | $6.2044 | $5.7332 | $7.7423 | -53.87% |
April, 2026 | $6.0298 | $5.0698 | $7.1157 | -55.17% |
May, 2026 | $6.0682 | $5.3532 | $7.7419 | -54.88% |
June, 2026 | $5.9165 | $5.6253 | $7.3624 | -56.01% |
July, 2026 | $4.712 | $3.4849 | $6.1407 | -64.97% |
August, 2026 | $5.5103 | $3.8991 | $5.5703 | -59.03% |
September, 2026 | $5.1957 | $4.6537 | $5.8474 | -61.37% |
October, 2026 | $4.4441 | $4.2341 | $5.757 | -66.96% |
November, 2026 | $4.7524 | $3.7683 | $5.0212 | -64.67% |
December, 2026 | $4.0479 | $1.7657 | $4.9995 | -69.90% |
Cullinan Therapeutics Inc Stock (CGEM) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Cullinan Therapeutics Inc (CGEM) is $7.9342, with a high forecast of $13.99 and a low forecast of $1.8788. This indicates an -41.01% decrease from the last price of $13.45.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2027 | $7.0762 | $3.6349 | $7.7591 | -47.39% |
February, 2027 | $5.7745 | $3.8545 | $7.5533 | -57.07% |
March, 2027 | $4.90 | $3.89 | $6.2441 | -63.57% |
April, 2027 | $4.9683 | $3.9171 | $5.5031 | -63.06% |
May, 2027 | $3.1967 | $3.1667 | $5.3954 | -76.23% |
June, 2027 | $3.5121 | $1.9854 | $3.5921 | -73.89% |
July, 2027 | $2.9704 | $2.2783 | $4.5063 | -77.92% |
August, 2027 | $2.4788 | $1.8788 | $3.4317 | -81.57% |
September, 2027 | $5.7842 | $2.2659 | $5.8442 | -56.99% |
October, 2027 | $13.00 | $5.8413 | $13.41 | -3.33% |
November, 2027 | $12.84 | $11.18 | $13.99 | -4.53% |
December, 2027 | $11.39 | $9.3321 | $13.28 | -15.34% |
Cullinan Therapeutics Inc Stock (CGEM) Price Forecast for 2028
In 2028, Cullinan Therapeutics Inc (CGEM) is projected to reach an average price of $26.51, with a high projection of $46.00 and a low estimate of $7.0136. This indicates an +97.09% rise from the last price of $13.45.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2028 | $21.40 | $9.5805 | $23.51 | +59.14% |
February, 2028 | $24.08 | $13.05 | $25.56 | +79.02% |
March, 2028 | $30.67 | $19.41 | $40.03 | +128.02% |
April, 2028 | $27.87 | $22.54 | $46.00 | +107.18% |
May, 2028 | $18.73 | $15.29 | $28.91 | +39.23% |
June, 2028 | $16.05 | $12.88 | $20.77 | +19.36% |
July, 2028 | $13.88 | $10.94 | $24.00 | +3.20% |
August, 2028 | $12.26 | $10.77 | $16.36 | -8.84% |
September, 2028 | $14.65 | $9.0552 | $15.64 | +8.90% |
October, 2028 | $15.31 | $12.97 | $16.89 | +13.86% |
November, 2028 | $10.47 | $8.5769 | $16.07 | -22.19% |
December, 2028 | $9.8419 | $7.0136 | $11.70 | -26.83% |
Cullinan Therapeutics Inc Stock (CGEM) Price Forecast for 2029
The 2029 price forecast for Cullinan Therapeutics Inc Stock (CGEM) is $5.3265 on average, with a high prediction of $10.63 and a low estimate of $0.027. This represents an -60.40% decrease from the previous price of $13.45.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2029 | $2.9728 | $2.7328 | $10.63 | -77.90% |
February, 2029 | $2.2494 | $1.2011 | $4.7711 | -83.28% |
March, 2029 | $0.2839 | $0.4672 | $5.2936 | -97.89% |
April, 2029 | $1.2028 | $0.1213 | $1.9587 | -91.06% |
May, 2029 | $0.3337 | $0.2047 | $1.9562 | -97.52% |
June, 2029 | $1.1896 | $1.5721 | $1.8338 | -91.16% |
July, 2029 | $2.5729 | $2.0455 | $1.7529 | -80.87% |
August, 2029 | $1.2621 | $2.2521 | $2.1788 | -90.62% |
September, 2029 | $0.0646 | $0.5096 | $0.9921 | -99.52% |
October, 2029 | $0.8255 | $0.0288 | $3.1913 | -93.86% |
November, 2029 | $0.1821 | $0.027 | $2.3838 | -98.65% |
December, 2029 | $0.0812 | $0.0685 | $1.4497 | -99.40% |
Cullinan Therapeutics Inc Stock (CGEM) Price Forecast for 2030
Cullinan Therapeutics Inc Stock (CGEM) is expected to reach an average price of $1.0116 in 2030, with a high forecast of $2.0185 and a low forecast of $0.00473. This signifies an -92.48% decrease from the last price of $13.45.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2030 | $0.2203 | $0.3386 | $0.8514 | -98.36% |
February, 2030 | $0.1536 | $0.458 | $1.4989 | -98.86% |
March, 2030 | $0.2769 | $0.00473 | $1.1547 | -97.94% |
April, 2030 | $1.7802 | $1.1228 | $1.6452 | -86.76% |
May, 2030 | $0.6194 | $1.0594 | $0.9261 | -95.39% |
June, 2030 | $1.2027 | $0.8852 | $0.7427 | -91.06% |
July, 2030 | $1.6218 | $1.0994 | $0.7618 | -87.94% |
August, 2030 | $1.2851 | $2.1051 | $1.6018 | -90.44% |
September, 2030 | $2.8485 | $2.571 | $2.0185 | -78.82% |
October, 2030 | $1.1024 | $0.4476 | $1.7782 | -91.80% |
November, 2030 | $0.1709 | $0.1016 | $1.5866 | -98.73% |
December, 2030 | $1.8742 | $1.4467 | $1.2142 | -86.07% |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):